

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS EXPRESS		FEBRUARY 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:32:15 ON 13 APR 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:32:30 ON 13 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2008 HIGHEST RN 1013911-12-0

DICTIONARY FILE UPDATES: 11 APR 2008 HIGHEST RN 1013911-12-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\1059788.str



```

chain nodes :
11 12 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
ring/chain nodes :
10
chain bonds :
4-10 5-21 6-12 7-15 8-11 22-23 23-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 4-10 5-6 5-21 6-12 8-9 8-11 22-23
exact bonds :
2-7 7-8 7-15 23-24
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 15 :
```

G1:H,CH3



```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:Atom
```

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\1059788.str



```
chain nodes :
11 12 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
ring/chain nodes :
10
chain bonds :
4-10 5-21 6-12 7-15 8-11 22-23 23-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 4-10 5-6 5-21 6-12 8-9 8-11 22-23
exact bonds :
2-7 7-8 7-15 23-24
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 15 :
```

G1:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:Atom

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 12 sam

SAMPLE SEARCH INITIATED 16:33:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 649 TO ITERATE

100.0% PROCESSED 649 ITERATIONS

30 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 11452 TO 14508

PROJECTED ANSWERS: 272 TO 928

L3 30 SEA SSS SAM L2

=> s 12 ful

FULL SEARCH INITIATED 16:33:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 13371 TO ITERATE

100.0% PROCESSED 13371 ITERATIONS

786 ANSWERS

SEARCH TIME: 00.00.01

L4 786 SEA SSS FUL L2

=> fil capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 16:33:33 ON 13 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 13 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 11 Apr 2008 (20080411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14

L5 30 L4

=> d 15 ibib hitstr abs 1-30

L5 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1476389 CAPLUS

DOCUMENT NUMBER: 148:253971

TITLE: MPZP: A novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist

AUTHOR(S): Richardson, Heather N.; Zhao, Yu; Fekete, Eva M.; Funk, Cindy K.; Wirsching, Peter; Janda, Kim D.; Zorrilla, Eric P.; Koob, George F.

CORPORATE SOURCE: Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, 92037, USA

SOURCE: Pharmacology, Biochemistry and Behavior (2008), 88(4), 497-510

CODEN: PBBHAU; ISSN: 0091-3057

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 202579-76-8, MPZP

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (MPZP: CRF1 receptor antagonist)

RN 202579-76-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB The extrahypothalamic stress peptide corticotropin-releasing factor (CRF) system is an important regulator of behavioral responses to stress. Dysregulation of CRF and the CRF type 1 receptor (CRF1) system is hypothesized to underlie many stress-related disorders. Modulation of the CRF1 system by non-peptide antagonists currently is being explored as a therapeutic approach for anxiety disorders and alc. dependence. Here, we describe a new, less hydrophilic (cLogP .apprx. 2.95), small mol., non-peptide CRF1 antagonist with high affinity ($K_i = 4.9$ nM) and specificity for CRF1 receptors: N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo[1,5-a] pyrimidin-7-amine (MPZP). The compound was systemically administered to adult male rats in two behavioral models dependent on the CRF1 system: defensive burying (0, 5, 20 mg/kg, $n = 6-11$ for each dose) and alc. dependence (0, 5, 10, 20 mg/kg, $n = 8$ for each self-administration group). Acute administration of MPZP reduced burying behavior in the defensive burying model of active anxiety-like behavior. MPZP also attenuated withdrawal-induced excessive drinking in the self-administration model of alc. dependence without affecting nondependent alc. drinking or water consumption. The present findings support the proposed significance of the CRF1 system in anxiety and alc. dependence and introduce a promising new compound for further development in the treatment of alc. dependence and stress-related disorders.

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1364083 CAPLUS
DOCUMENT NUMBER: 148:1117
TITLE: Melatonin agonist for treatment of depressive disorders
INVENTOR(S): Wolfgang, Curt D.; Polymeropoulos, Mihael H.
PATENT ASSIGNEE(S): Vanda Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007137227	A1	20071129	WO 2007-US69373	20070521
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-747861P P 20060522

IT 202579-74-6, DMP904 202579-74-6D, DMP904, metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melatonin agonist for treatment of depressive disorders)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB A method of treating depression comprising administering a melatonin agonist.

L5 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:409409 CAPLUS
DOCUMENT NUMBER: 146:428737
TITLE: Pyrazolo[1,5- α]pyrimidinyl derivatives useful as
corticotropin-releasing factor (CRF) receptor
antagonists
INVENTOR(S): Hossner, Frank
PATENT ASSIGNEE(S): Sb Pharmco Puerto Rico Inc, P. R.; Neurocrine
Biosciences Inc
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007039264	A1	20070412	WO 2006-EP9531	20060928
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006044958	A1	20060427	WO 2005-US37576	20051019
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			GB 2005-19957	A 20050930
			WO 2005-US37576	A 20051019
			US 2004-620060P	P 20041019

IT 885220-61-1P


RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of polymorphic form of pyrazolopyrimidinyl derivative and its composition useful as CRF receptor antagonist)

RN 885220-61-1 CAPLUS

CN Pyrazolo[1,5- α]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 885220-98-4P 885220-99-5P 885221-20-5P
933770-76-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of polymorphic form of pyrazolopyrimidinyl derivative and its composition useful as CRF receptor antagonist)

RN 885220-98-4 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (1-iminoethyl)azanyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-99-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 885220-61-1

CMF C22 H26 N6 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 885221-20-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 933770-76-4 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine (I), useful as a CRF receptor antagonist. The present invention also relates to pharmaceutical compns. comprising the same and methods of using the same. Thus, 0.74 g of compound I polymorph Form 1 (preparation given) was slurried in 50% aqueous isopropanol at a temperature cycled between 0 and 40° for 24 h, at ambient temperature for 3 days, and at the temperature cycled between 0 to 40° for 24 h, and the residue was filtered off and dried to give 0.70 g of compound I Form 2. Granules were prepared containing compound I polymorph Form 2 200.0%, HPMC 46.88%, sodium lauryl sulfate 3.13%, sodium croscarmellose 9.38%, and mannitol 53.11%. Coated tablets were then formulated comprising (i) cores containing 83.33% granules obtained, Avicel PH 102 12.67, sodium croscarmellose 3.0%, and magnesium stearate 1.0%, and (ii) coating of Opadry OY-S-28876 3.0%.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:173880 CAPLUS

DOCUMENT NUMBER: 146:229377

TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as anticancer drugs.

INVENTOR(S): Murphy, Finbarr; James, Theo Richard; Hayes, Ian

PATENT ASSIGNEE(S): Eirx Therapeutics Limited, Ire.

SOURCE: PCT Int. Appl., 91pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017678	A1	20070215	WO 2006-GB2968	20060808
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2005-16378 A 20050809

US 2005-706593P P 20050809

OTHER SOURCE(S): MARPAT 146:229377

IT 924902-14-7P 924902-16-9P 924902-18-1P


924902-19-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyrazolopyrimidines as anticancer drugs)


RN 924902-14-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 924902-16-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 924902-18-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 924902-19-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)



GI



I

AB Title compds. [I; Cy1 = (substituted) 5-10 membered mono- or bicyclic (hetero)aryl; R1-R3 = H, OH, halo, (substituted) alkyl, haloalkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, cyano, 5-6 membered heteroaryl, NO₂, amino, cyano, etc.; R4 = NHCy2; Cy2 = (substituted) cyclic group], were prepared Thus, 7-chloro-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (preparation given), 2-picolyamine, and diisopropylethylamine were heated in Me₂CHOH at 85° for 45 min. to give [3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]pyridin-2-ylmethylamine. The latter at 10 μM gave a 68% kill of MCF7 cells.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:382981 CAPLUS

DOCUMENT NUMBER: 144:432830

TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as corticotropin-releasing factor (CRF) receptor antagonists.

INVENTOR(S): Lanier, Marion; Luo, Zhiyong; Moorjani, Manisha; Tellew, John Edward; Williams, John P.; Zhang, Xiaohu

PATENT ASSIGNEE(S): Sb Pharmco Puerto Rico Inc., P. R.; Neurocrine Biosciences Inc.

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044958	A1	20060427	WO 2005-US37576	20051019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005295353	A1	20060427	AU 2005-295353	20051019
CA 2584567	A1	20060427	CA 2005-2584567	20051019
EP 1802627	A1	20070704	EP 2005-818308	20051019
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
CN 101084219	A	20071205	CN 2005-80043716	20051019
WO 2007039264	A1	20070412	WO 2006-EP9531	20060928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2007DN02733	A	20070803	IN 2007-DN2733	20070412
MX 200704701	A	20070614	MX 2007-4701	20070418
KR 2007088621	A	20070829	KR 2007-708794	20070418
NO 2007002541	A	20070625	NO 2007-2541	20070516
PRIORITY APPLN. INFO.:			US 2004-620060P	P 20041019
			GB 2005-19957	A 20050930
			WO 2005-US37576	W 20051019

OTHER SOURCE(S): MARPAT 144:432830


IT 885220-17-7P 885220-18-8P 885220-19-9P
 885220-20-2P 885220-21-3P 885220-22-4P
 885220-23-5P 885220-24-6P 885220-25-7P
 885220-26-8P 885220-27-9P 885220-28-0P
 885220-29-1P 885220-30-4P 885220-31-5P
 885220-32-6P 885220-34-8P 885220-35-9P
 885220-36-0P 885220-37-1P 885220-38-2P
 885220-41-7P 885220-42-8P 885220-43-9P
 885220-44-0P 885220-45-1P 885220-46-2P
 885220-47-3P 885220-48-4P 885220-49-5P
 885220-50-8P 885220-51-9P 885220-52-0P
 885220-53-1P 885220-54-2P 885220-55-3P
 885220-56-4P 885220-57-5P 885220-58-6P
 885220-59-7P 885220-60-0P 885220-61-1P
 885220-62-2P 885220-63-3P 885220-64-4P
 885220-65-5P 885220-68-8P 885220-69-9P
 885220-70-2P 885220-71-3P 885220-72-4P
 885220-73-5P 885220-74-6P 885220-75-7P
 885220-76-8P 885220-77-9P 885220-78-0P
 885220-79-1P 885220-80-4P 885220-81-5P
 885220-82-6P 885220-83-7P 885220-84-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(claimed compound; preparation of pyrazolopyrimidines as CRF receptor
 antagonists)


RN 885220-17-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-
 yl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-18-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-
 dimethyl-N-[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]propyl]- (CA INDEX
 NAME)



RN 885220-19-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenylethyl]- (CA INDEX NAME)




RN 885220-20-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)




RN 885220-21-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 885220-22-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-23-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 885220-24-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-25-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 885220-26-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]propyl]- (CA INDEX NAME)



RN 885220-27-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-28-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]- (CA INDEX NAME)




RN 885220-29-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-ethyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-30-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-propyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 885220-31-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]cyclopropyl]- (CA INDEX NAME)



RN 885220-32-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-34-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-[(2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-35-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)




RN 885220-36-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)




RN 885220-37-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)




RN 885220-38-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[3-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)




RN 885220-41-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)



RN 885220-42-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)




RN 885220-43-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885220-44-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)




RN 885220-45-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 885220-46-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl]-(CA INDEX NAME)



RN 885220-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-(CA INDEX NAME)


Absolute stereochemistry.



RN 885220-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl]-(CA INDEX NAME)


Absolute stereochemistry.




RN 885220-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-(CA INDEX NAME)


Absolute stereochemistry.




RN 885220-50-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]propyl]- (CA INDEX NAME)



RN 885220-51-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]propyl]-3-(2,4-dimethoxyphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-52-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]propyl]- (CA INDEX NAME)



RN 885220-53-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-54-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)



RN 885220-55-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-56-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-58-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-59-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-
 [(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-60-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-
 [(1S)-2,2,2-trifluoro-1-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-61-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-
 dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 885220-62-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-63-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-7-[(2S)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-65-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 885220-68-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-ethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 885220-69-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)



RN 885220-70-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-71-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-72-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-73-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-76-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 885220-78-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-7-[2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperidinyll]- (CA INDEX NAME)




RN 885220-79-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(1,3,4-oxadiazol-2-yl)propyl]- (CA INDEX NAME)




RN 885220-80-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(5-methyl-1,3,4-oxadiazol-2-yl)propyl]- (CA INDEX NAME)



RN 885220-81-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]- (CA INDEX NAME)




RN 885220-82-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]ethyl]- (CA INDEX NAME)




RN 885220-83-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)




RN 885220-84-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)



IT 885221-15-8P 885221-17-0P 885221-18-1P
 885221-19-2P 885221-20-5P 885221-21-6P
 885221-22-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 RN 885221-15-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-
 dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)




RN 885221-17-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N,2,5-trimethyl-
 N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 885221-18-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-19-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]-, hydrochloride (1:?) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 885221-20-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 885221-21-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-22-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


IT 885220-94-0P 885220-95-1P 885220-96-2P
 885220-97-3P 885220-98-4P 885220-99-5P
 885221-01-2P 885221-02-3P 885221-03-4P
 885221-04-5P 885221-05-6P 885221-06-7P
 885221-07-8P 885221-08-9P 885221-09-0P
 885221-10-3P 885221-11-4P 885221-12-5P
 885221-13-6P 885221-14-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 885220-94-0 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (CA INDEX NAME)



RN 885220-95-1 CAPLUS


CN Butanoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, ethyl ester (CA INDEX NAME)



RN 885220-96-2 CAPLUS

CN L-Norvaline, N-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-97-3 CAPLUS


CN L-Norvaline, N-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-98-4 CAPLUS
 CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (1-iminoethyl)azanyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-99-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 885220-61-1
 CMF C22 H26 N6 O2


Absolute stereochemistry.



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 885221-01-2 CAPLUS


CN Glycine, N-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-methoxyethyl)-, methyl ester (CA INDEX NAME)



RN 885221-02-3 CAPLUS

CN Butanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-03-4 CAPLUS

CN Butanoic acid, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-04-5 CAPLUS

CN Butanoic acid, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-05-6 CAPLUS

CN Butanamide, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-06-7 CAPLUS


CN Butanenitrile, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885221-07-8 CAPLUS

CN Glycine, N-ethyl-N-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (CA INDEX NAME)




RN 885221-08-9 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, hydrazide (CA INDEX NAME)




RN 885221-09-0 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-formylhydrazide (CA INDEX NAME)



RN 885221-10-3 CAPLUS


CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-acetylhydrazide (CA INDEX NAME)



RN 885221-11-4 CAPLUS


CN Butaneperoxoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (CA INDEX NAME)




RN 885221-12-5 CAPLUS

CN Butanoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, hydrazide (CA INDEX NAME)




RN 885221-13-6 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-acetylhydrazide (CA INDEX NAME)




RN 885221-14-7 CAPLUS

CN Butanoic acid, 2-[[3-(2-chloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (CA INDEX NAME)



GI




AB Title compds. [I; R1 = H, (substituted) alkyl, haloalkyl, alkoxyalkyl, aralkyl, heterocycloalkyl; R2a, R2b = H, (substituted) alkyl, haloalkyl, aralkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl; R1R2a, R1R2b = atoms to form 4-7 membered ring; Y = bond, C(R4aR4b)m; m = 1, 2; R4a, R4b = H, (substituted) alkyl, aralkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl; R4aR4bC = atoms to form a 3-7 membered ring; Het = (substituted) oxadiazolyl; n = 0-3; R6 = H, (substituted) alkyl; R7 = H, (substituted) alkyl, alkoxy, amino, alkylsulfonyl; p = 0-3; Ar = Ph, pyridyl], were prepared Thus, [3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]amine (multistep preparation given) showed CRF receptor binding affinity with Ki <100 nM.


REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:962100 CAPLUS
 DOCUMENT NUMBER: 143:266943
 TITLE: CRF receptor antagonists, their preparations, their pharmaceutical composition and their uses
 INVENTOR(S): Slee, Deborah; Grigoriadis, Dimitri; Williams, John
 PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.; Glaxo Group Limited
 SOURCE: PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079868	A2	20050901	WO 2005-GB432	20050209
WO 2005079868	A3	20060126		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			SM
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1722826	A2	20061122	EP 2005-708257	20050209
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
JP 2008503444	T	20080207	JP 2006-552678	20050209
US 20070129382	A1	20070607	US 2006-597788	20060808
PRIORITY APPLN. INFO.:			US 2004-544758P	P 20040213
			WO 2005-GB432	W 20050209
OTHER SOURCE(S):	CASREACT 143:266943			
IT	863550-35-0P 863550-36-1P 863550-37-2P 863550-39-4P 863550-40-7P			
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of pyrazolopyrimidine derivs. as CRF receptor antagonists)			
RN	863550-35-0 CAPLUS			
CN	Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)			



RN 863550-36-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(methoxy-
 11C)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 863550-37-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-ethyl-N-[2-(
 (fluoro-18F)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 863550-39-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-(2,4-dimethoxyphenyl)-7-[(2R)-2-(
 methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 863550-40-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-ethyl-N-(2-
 methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



GI




I

AB CRF receptor antagonists 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-(diethylamino)pyrazolo[2,3-a]pyrimidine (I), 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-(N-ethyl-N-methoxyethylamino)pyrazolo[2,3-a]pyrimidine, 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-(2-(S)-methoxymethylpyrrolidinyl)pyrazolo[2,3-a]pyrimidine, and 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-[N-ethyl-N-(2-fluoroethyl)amino]pyrazolo[2,3-a]pyrimidine were prepared and have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals. CRF receptor antagonists which are labeled with a positron emitting isotope for use in PET are also prepared. Thus, I was prepared in 7 steps starting from 3,4-dimethoxybenzaldehyde.

L5 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:962049 CAPLUS
 DOCUMENT NUMBER: 143:254020
 TITLE: Therapeutic combinations of atypical antipsychotics
 with corticotropin releasing factor antagonists
 INVENTOR(S): Romano, Steven Joseph
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079807	A1	20050901	WO 2005-IB251	20050201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005215257	A1	20050901	AU 2005-215257	20050201
CA 2556160	A1	20050901	CA 2005-2556160	20050201
EP 1718311	A1	20061108	EP 2005-702400	20050201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1917882	A	20070221	CN 2005-80004943	20050201
BR 2005007609	A	20070703	BR 2005-7609	20050201
JP 2007522200	T	20070809	JP 2006-552710	20050201
US 20050209250	A1	20050922	US 2005-58329	20050214
IN 2006DN04617	A	20070810	IN 2006-DN4617	20060810
MX 2006PA09271	A	20061207	MX 2006-PA9271	20060814
NO 2006004054	A	20061110	NO 2006-4054	20060908
PRIORITY APPLN. INFO.:			US 2004-544731P	P 20040213
			WO 2005-IB251	W 20050201

OTHER SOURCE(S): MARPAT 143:254020
 IT 195054-99-0 202579-86-0
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists)
 RN 195054-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB The present invention is directed to a pharmaceutical compns. for treating, for example, mood disorders or conditions, psychotic disorders or conditions, or a combination thereof, in a mammal such as a human, the composition comprising (a) an atypical antipsychotic, a prodrug thereof or a pharmaceutically acceptable salt of the atypical antipsychotic or prodrug thereof, (b) a corticotropin releasing factor antagonist, a prodrug thereof, or pharmaceutically acceptable salt of said corticotropin releasing factor antagonist or prodrug thereof, and optionally (c) a pharmaceutically acceptable vehicle, carrier or diluent. A pharmaceutical composition is prepared containing ziprasidone with a corticotropin releasing factor antagonist such a 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)pyridine.


REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:612294 CAPLUS
DOCUMENT NUMBER: 143:133390
TITLE: Preparation of pyrazolopyrimidines as CRF receptor antagonists
INVENTOR(S): Luo, Zhiyong; Slee, Deborah; Tellew, John Edward; Williams, John; Zhang, Xiahou
PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063756	A1	20050714	WO 2004-IB4293	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1697369	A1	20060906	EP 2004-806458	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007515474	T	20070614	JP 2006-546400	20041220
US 20070293511	A1	20071220	US 2007-596646	20070529
PRIORITY APPLN. INFO.:			US 2003-532044P	P 20031222
			WO 2004-IB4293	W 20041220
OTHER SOURCE(S):			CASREACT 143:133390; MARPAT 143:133390	
IT 858520-93-1P 858521-24-1P 858523-08-7P				
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
(preparation of pyrazolopyrimidines as CRF receptor antagonists)				
RN 858520-93-1 CAPLUS				
CN 2-Pyrrolidinemethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, (2S)- (CA INDEX NAME)				

Absolute stereochemistry.



RN 858521-24-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858523-08-7 CAPLUS

CN Butanoic acid, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 858520-82-8P 858520-83-9P 858520-84-0P
858520-85-1P 858520-86-2P 858520-88-4P
858520-90-8P 858520-91-9P 858520-92-0P

858520-95-3P 858520-97-5P 858520-98-6P
858520-99-7P 858521-01-4P 858521-02-5P
858521-03-6P 858521-04-7P 858521-05-8P
858521-06-9P 858521-07-0P 858521-08-1P
858521-09-2P 858521-10-5P 858521-11-6P
858521-12-7P 858521-13-8P 858521-14-9P
858521-15-0P 858521-16-1P 858521-17-2P
858521-18-3P 858521-19-4P 858521-20-7P
858521-21-8P 858521-22-9P 858521-23-0P
858521-25-2P 858521-26-3P 858521-27-4P
858521-28-5P 858521-29-6P 858521-30-9P
858521-31-0P 858521-32-1P 858521-33-2P
858521-34-3P 858521-35-4P 858521-36-5P
858521-37-6P 858521-38-7P 858521-39-8P
858521-40-1P 858521-41-2P 858521-42-3P
858521-43-4P 858521-44-5P 858521-45-6P
858521-46-7P 858521-47-8P 858521-48-9P
858521-49-0P 858521-50-3P 858521-51-4P
858521-52-5P 858521-53-6P 858521-54-7P
858521-55-8P 858521-56-9P 858521-57-0P
858521-58-1P 858521-59-2P 858521-60-5P
858521-61-6P 858521-62-7P 858521-63-8P
858521-64-9P 858521-65-0P 858521-66-1P
858521-67-2P 858521-68-3P 858521-69-4P
858521-70-7P 858521-71-8P 858521-72-9P
858521-73-0P 858521-74-1P 858521-75-2P
858521-76-3P 858521-77-4P 858521-78-5P
858521-79-6P 858521-80-9P 858521-81-0P
858521-82-1P 858521-83-2P 858521-84-3P
858521-85-4P 858521-86-5P 858521-87-6P
858521-88-7P 858521-89-8P 858521-90-1P
858521-91-2P 858521-92-3P 858521-93-4P
858521-94-5P 858521-95-6P 858521-96-7P
858521-97-8P 858521-98-9P 858521-99-0P
858522-00-6P 858522-01-7P 858522-02-8P
858522-03-9P 858522-04-0P 858522-05-1P
858522-06-2P 858522-07-3P 858522-08-4P
858522-09-5P 858522-10-8P 858522-11-9P
858522-12-0P 858522-13-1P 858522-14-2P
858522-15-3P 858522-17-5P 858522-18-6P
858522-19-7P 858522-20-0P 858522-21-1P
858522-22-2P 858522-23-3P 858522-24-4P
858522-25-5P 858522-26-6P 858522-27-7P
858522-28-8P 858522-29-9P 858522-30-2P
858522-32-4P 858522-33-5P 858522-34-6P
858522-35-7P 858522-36-8P 858522-37-9P
858522-38-0P 858522-39-1P 858522-40-4P
858522-41-5P 858522-42-6P 858522-43-7P
858522-44-8P 858522-45-9P 858522-46-0P
858522-47-1P 858522-48-2P 858522-49-3P
858522-50-6P 858522-51-7P 858522-52-8P
858522-53-9P 858522-54-0P 858522-55-1P
858522-56-2P 858522-57-3P 858522-58-4P
858522-59-5P 858522-60-8P 858522-61-9P
858522-62-0P 858522-63-1P 858522-64-2P
858522-65-3P 858522-66-4P 858522-67-5P
858522-68-6P 858522-69-7P 858522-70-0P
858522-71-1P 858522-72-2P 858522-73-3P
858522-74-4P 858522-75-5P 858522-76-6P


858522-77-7P 858522-78-8P 858522-80-2P
 858522-82-4P 858522-83-5P 858522-84-6P
 858522-85-7P 858522-86-8P 858522-87-9P
 858522-88-0P 858522-89-1P 858522-90-4P
 858522-91-5P 858522-92-6P 858522-93-7P
 858523-09-8P 858523-14-5P 858523-15-6P
 858523-19-0P 858523-20-3P 858523-21-4P
 858523-22-5P 858523-23-6P 858523-24-7P
 858523-25-8P 858523-26-9P 858523-27-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 858520-82-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858520-83-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-
 dimethyl-7-(4-morpholinyl)- (CA INDEX NAME)




RN 858520-84-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-[2-methoxy-4-
 (1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-85-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858520-86-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (CA INDEX NAME)



RN 858520-88-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858520-90-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858520-91-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,N,2,5-tetramethyl- (CA INDEX NAME)




RN 858520-92-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-95-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-97-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-98-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(1-azetidiny)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-99-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-01-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-methylpropyl)- (CA INDEX NAME)




RN 858521-02-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,1-dimethylethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-03-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 858521-04-7 CAPLUS
 CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]methylamino]- (CA INDEX NAME)




RN 858521-05-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-06-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)




RN 858521-07-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(1H-benzimidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-08-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-09-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(1-methylethyl)-1H-imidazol-1-yl]- (CA INDEX NAME)




RN 858521-10-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,4-dimethyl-1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-11-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)-N-propyl- (CA INDEX NAME)




RN 858521-12-7 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methyl-, methyl ester (CA INDEX NAME)




RN 858521-13-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)




RN 858521-14-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 858521-15-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,3-dihydro-1H-indol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-16-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-4-methyl-1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-17-2 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methyl- (CA INDEX NAME)




RN 858521-18-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 858521-19-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-20-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(3,6-dihydro-1(2H)-pyridinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-21-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-22-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 858521-23-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 858521-25-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858521-26-3 CAPLUS
 CN 1,2-Ethanediamine, N-ethyl-N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-27-4 CAPLUS
 CN 1,2-Ethanediamine, N,N,N'-triethyl-N'-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 858521-28-5 CAPLUS

CN 2-Piperidineethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-29-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-propyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-30-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(methoxymethyl)-1-piperidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-31-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(2-methoxyethyl)-1-piperidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-32-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,6-dimethyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-33-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-34-3 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)



RN 858521-35-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 858521-36-5 CAPLUS
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-37-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(3,3-dimethyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-38-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(5-ethyl-2-methyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-39-8 CAPLUS

CN 4-Piperidinol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-40-1 CAPLUS

CN 1,2-Ethanediamine, N1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N1,N2,N2-trimethyl-1-phenyl- (CA INDEX NAME)




RN 858521-41-2 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N',N'-tris(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858521-42-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 858521-43-4 CAPLUS

CN 4-Piperidineethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-44-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-(4-fluorophenyl)ethyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-45-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-piperidinyl)- (CA INDEX NAME)




RN 858521-46-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-47-8 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-48-9 CAPLUS

CN Ethanol, 2-[ethyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858521-49-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[(2R,4S)-4-fluoro-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 858521-50-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[3-(trifluoromethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 858521-51-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2,6-dichlorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-52-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-6-methylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-53-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2,6-difluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-54-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-

N,2,5-trimethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 858521-55-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858521-56-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[3-(methoxymethyl)-1-piperidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-57-0 CAPLUS

CN Benzenesulfonamide, 4-[[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)




RN 858521-58-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 858521-59-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-furanylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-60-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 858521-61-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-62-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)



RN 858521-63-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 858521-64-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 858521-65-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 858521-66-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-67-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-68-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 858521-69-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-70-7 CAPLUS

CN 1-Butanol, 2-[[3-[[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-(4-fluorophenylmethyl)]- (CA INDEX NAME)




RN 858521-71-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-72-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 858521-73-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[3-(difluoromethoxy)phenyl]methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-74-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3,4-difluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-75-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-chlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-76-3 CAPLUS

CN Benzonitrile, 3-chloro-4-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-5-methyl- (CA INDEX NAME)




RN 858521-77-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-4,6-dimethylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-78-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-4,6-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-79-6 CAPLUS

CN Benzonitrile, 3,5-dichloro-2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858521-80-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-fluoro-6-(trifluoromethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-81-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[3-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 858521-82-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-chloro-4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-83-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-chlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-84-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[4-(difluoromethoxy)phenyl]methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-85-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3,4-dichlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-86-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)




RN 858521-87-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 858521-88-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[5-(2-pyridinyl)-2-thienyl]methyl]- (CA INDEX NAME)




RN 858521-89-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 858521-90-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(3-methyl-2-thienyl)methyl]- (CA INDEX NAME)




RN 858521-91-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]- (CA INDEX NAME)




RN 858521-92-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(2,5-dimethyl-3-furanyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-93-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RN 858521-94-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3,5-dimethyl-4-isoxazolyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-95-6 CAPLUS


CN 1-Butanol, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 858521-96-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858521-97-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)




RN 858521-98-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,N-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 858521-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)




RN 858522-00-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)



RN 858522-01-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-02-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1H-pyrrolo[2,3-b]pyridin-1-yl)- (CA INDEX NAME)




RN 858522-03-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-1H-pyrrol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-04-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[4-(1H-imidazol-1-yl)-2-methoxyphenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 858522-05-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858522-06-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858522-07-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-08-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-1,2,3-triazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-09-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(4-methyl-1H-pyrazol-1-yl)phenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-10-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[4-(1H-imidazol-1-yl)-2-methoxyphenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 858522-11-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 1-[3-methoxy-4-[7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-12-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-13-1 CAPLUS


CN 1H-Pyrrole-2-carbonitrile, 1-[3-methoxy-4-[7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-14-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrrol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858522-15-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrrol-1-yl)phenyl]-2,5-dimethyl-N-(3,3,3-trifluoropropyl)- (CA INDEX NAME)




RN 858522-17-5 CAPLUS

CN Propanedioic acid, ethyl [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 858522-16-4
CMF C28 H32 N6 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 858522-18-6 CAPLUS
CN 2-Thiophenecarboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-19-7 CAPLUS

CN Propanoic acid, 3-(methylthio)-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-20-0 CAPLUS

CN Pentanedioic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-21-1 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxylic acid, 4-methyl-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-22-2 CAPLUS

CN Cyclobutanecarboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-23-3 CAPLUS

CN Cyclopropanecarboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-24-4 CAPLUS

CN 4-Pyridinecarboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-25-5 CAPLUS

CN Acetic acid, methoxy-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-26-6 CAPLUS

CN Carbonic acid, ethyl [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 858522-27-7 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, propanoate (ester), (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 858522-28-8 CAPLUS

CN Propanedioic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-29-9 CAPLUS

CN Propanoic acid, 2-methyl-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-30-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, acetate (ester), (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858522-32-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(ethoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858522-31-3

CMF C25 H30 N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 858522-33-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-[(2,2-dimethoxyethoxy)methyl]-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-34-6 CAPLUS

CN Acetonitrile, [[(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-35-7 CAPLUS


CN Acetic acid, [[(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-36-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-fluoroethyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-37-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-fluoroethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-38-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-fluoroethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (CA INDEX NAME)



RN 858522-39-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 858522-40-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 858522-41-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-42-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-43-7 CAPLUS

CN Benzonitrile, 3-[[2-methoxyethyl][3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)




RN 858522-44-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,3-benzodioxol-5-ylmethyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-45-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-fluorophenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-46-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-47-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(2-methyl-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 858522-48-2 CAPLUS

CN Benzonitrile, 4-[[(2-methoxyethyl) [3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)




RN 858522-49-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-50-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[3-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
(CA INDEX NAME)




RN 858522-51-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]-
(CA INDEX NAME)




RN 858522-52-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 858522-53-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 858522-54-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[2-(trifluoromethoxy)phenyl]methyl]-
(CA INDEX NAME)




RN 858522-55-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[2-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
(CA INDEX NAME)




RN 858522-56-2 CAPLUS

CN 1,2-Ethanediamine, N-[(4-fluorophenyl)methyl]-N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-57-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 858522-58-4 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 858522-59-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 858522-60-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-61-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-62-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 858522-63-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]-
(CA INDEX NAME)




RN 858522-64-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-[[3-methoxyphenyl]methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
(CA INDEX NAME)




RN 858522-65-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 858522-66-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 858522-67-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 858522-68-6 CAPLUS

CN Propanenitrile, 3-[ethyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858522-69-7 CAPLUS

CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)




RN 858522-70-0 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858522-71-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[3-(1H-imidazol-1-yl)propyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-72-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 858522-73-3 CAPLUS


CN Propanenitrile, 3-[[2-(3,4-dimethoxyphenyl)ethyl][3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 858522-74-4 CAPLUS
 CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](2-thienylmethyl)amino]- (CA INDEX NAME)




RN 858522-75-5 CAPLUS
 CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl][2-(2-pyridinyl)ethyl]amino]- (CA INDEX NAME)




RN 858522-76-6 CAPLUS

CN Propanenitrile, 3-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl][3-(4-morpholinyl)propyl]amino]-(CA INDEX NAME)




RN 858522-77-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl-N-(tetrahydro-2H-pyran-4-yl)-(CA INDEX NAME)




RN 858522-78-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 858522-80-2 CAPLUS
 CN Butanoic acid, 4-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 858522-79-9
 CMF C29 H30 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 858522-82-4 CAPLUS

CN Butanoic acid, 4-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858522-81-3


CMF C31 H34 N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 858522-83-5 CAPLUS

CN Heptanoic acid, 7-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 858522-84-6 CAPLUS

CN Octanoic acid, 8-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 858522-85-7 CAPLUS

CN Pentanoic acid, 5-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 858522-86-8 CAPLUS

CN Hexanoic acid, 6-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 858522-87-9 CAPLUS

CN Heptanoic acid, 7-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)




RN 858522-88-0 CAPLUS

CN Pentanoic acid, 5-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)




RN 858522-89-1 CAPLUS

CN Hexanoic acid, 6-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)




RN 858522-90-4 CAPLUS

CN Octanoic acid, 8-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)




RN 858522-91-5 CAPLUS

CN β -Alanine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(phenylmethyl)-, ethyl ester (CA INDEX NAME)




RN 858522-92-6 CAPLUS

CN β -Alanine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 858522-93-7 CAPLUS


CN Nonanoic acid, 9-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)



RN 858523-09-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 858523-14-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3,3,3-trifluoropropyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858523-13-4


CMF C24 H27 F3 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 858523-15-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-fluoropropyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858523-19-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[4-(3-furanyl)-2-methoxyphenyl]-N-(2-methoxyethyl)-2,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858523-18-9


CMF C24 H28 N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 858523-20-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858523-21-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(3-pyridinyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858523-22-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858523-23-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(3-thienyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858523-24-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[4-(2-furanyl)-2-methoxyphenyl]-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 858523-25-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(2-thienyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858523-26-9 CAPLUS
 CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[7-[ethyl(2-methoxyethyl)amino]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-3-methoxyphenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 858523-27-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(2-oxazolyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 858523-70-3 858523-71-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RN 858523-70-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-bromo-2-methoxyphenyl)-N-ethyl-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 858523-71-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-bromo-2-methoxyphenyl)-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 858523-42-9P 858523-43-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 RN 858523-42-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-bromo-2-methoxyphenyl)-2,5-dimethyl-
 N-(1-methylethyl)- (CA INDEX NAME)



RN 858523-43-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-iodo-2-methoxyphenyl)-2,5-dimethyl-
 N-(1-methylethyl)- (CA INDEX NAME)



GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, NH2, (un)substituted alkyl, etc.; R2 = NR5R6 or
 OR7; R3 = H, alkyl or absent if double bond is present; Y = CO, =(CR4)-;

R4 = H, thioalkyl, (un)substituted alkyl, etc.; Ar = (un)substituted Ph or pyridyl; Het = (un)substituted heteroaryl; R5 = H, (un)substituted alkyl, heterocycle, etc.; R6 = (un)substituted alkyl, heterocyclealkyl, aryl, etc.; R7 = (un)substituted alkyl, arylalkyl, heteroarylalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as CRF receptor antagonists. Thus, e.g., II was prepared by cyclization of III (preparation given) with Et acetoacetate followed by chlorination and subsequent substitution with isopropylamine. The CRF receptor binding activity of I was evaluated using radioligand binding assay (no data). I as CRF receptor antagonists should prove useful in the treatment of stroke, depression and anxiety. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:461608 CAPLUS
 DOCUMENT NUMBER: 143:185966
 TITLE: The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists
 AUTHOR(S): Li, Yu-Wen; Fitzgerald, Lawrence; Wong, Harvey; Lelas, Snjezana; Zhang, Ge; Lindner, Mark D.; Wallace, Tanya; McElroy, John; Lodge, Nicholas J.; Gilligan, Paul; Zaczek, Robert
 CORPORATE SOURCE: Neuroscience Biology, Medicinal Chemistry, Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA
 SOURCE: CNS Drug Reviews (2005), 11(1), 21-52
 CODEN: CDREFB; ISSN: 1080-563X
 PUBLISHER: Neva Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 202579-74-6, DMP904
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. properties suggested that non-peptidergic CRF1 receptor antagonists DMP696 and DMP904 may be effective anxiolytics with low behavioral side effect liabilities in rat model of anxiety)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB A review. CRF1 antagonists DMP696 and DMP904 were designed as drug development candidates for the treatment of anxiety and depression. Both compds. display nanomolar affinity for human CRF1 receptors, and exhibit > 1000-fold selectivity for CRF1 over CRF2 receptors and over a broad panel of other proteins. DMP696 and DMP904 block CRF-stimulated adenylyl cyclase activity in cortical homogenates and cell-lines expressing CRF1 receptors. Both compds. inhibit CRF-stimulated ACTH release from rat pituitary corticotropes. Binding and functional studies indicate that DMP696 and DMP904 behave as noncompetitive full antagonists. DMP696 and DMP904 exhibit anxiolytic-like efficacy in several rat anxiety models. In the defensive withdrawal test, both compds. reduce exit latency with lowest EDs of 3 and 1 mg/kg, resp. The anxiolytic-like effect is maintained over 14 days of repeated dosing. In the context of a novel environment used in this test, DMP696 and DMP904 reverse mild stress-induced increases in plasma CORT secretion but at doses 3-4-fold greater than those required for anxiolytic-like efficacy. DMP696 and DMP904 are ineffective in three depression models including the learned helplessness paradigm at doses up to 30 mg/kg. At lowest anxiolytic-like doses, DMP696 and DMP904 occupy >50% CRF1 receptors in the brain. The in vivo IC50 values (plasma concns. required for occupying 50% CRF1

receptors) estimated based upon free, but not total, plasma concns. are an excellent correlation with the in vitro IC50 values. Neither compound produces sedation, ataxia, chlordiazepoxide-like subjective effects or adverse effects on cognition at doses 10-fold higher than anxiolytic-like doses. Neither compound produces physiol. significant changes in cardiovascular, respiratory, gastrointestinal or renal functions at anxiolytic-like doses. DMP696 and DMP904 have favorable pharmacokinetic profiles with good oral bioavailabilities. The overall pharmacol. properties suggest that both compds. may be effective anxiolytics with low behavioral side effect liabilities.

REFERENCE COUNT: 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2005:268104 CAPLUS
 DOCUMENT NUMBER: 143:19806
 TITLE: Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats
 AUTHOR(S): Wong, Harvey; Lehman-McKeeman, Lois D.; Grubb, Mary F.; Grossman, Scott J.; Bhaskaran, Vasanthi M.; Solon, Eric G.; Shen, Helen S. L.; Gerson, Ronald J.; Car, Bruce D.; Zhao, Bitao; Gemzik, Brian
 CORPORATE SOURCE: Departments of Metabolism and Pharmacokinetics, Discovery Toxicology and Biotransformation, Pharmaceutical Candidate Optimization, 5 Research Parkway, Wallingford, Connecticut, Bristol-Myers Squibb Company, Princeton, NJ, 08543, USA
 SOURCE: Toxicological Sciences (2005), 84(2), 232-242
 CODEN: TOSCF2; ISSN: 1096-6080
 PUBLISHER: Oxford University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (increased hepatobiliary clearance of unconjugated thyroxine dets. DMP 904-induced alterations in thyroid hormone homeostasis in rats)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB 4-(3-Pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904) is a potent and selective antagonist of corticotropin releasing factor receptor-1 (CRF1 receptor) with an efficacious anxiolytic profile in preclin. animal models. In subchronic toxicity studies in Sprague-Dawley rats, DMP 904 produced thyroid follicular cell hypertrophy and hyperplasia, and a low incidence of follicular cell adenoma. The current investigations were designed to determine the mode of action by which DMP 904 disrupts thyroid homeostasis in male rats. Five-day treatment with DMP 904 (300 mg/kg/day) dramatically lowered serum thyroxine (T4) to levels below detectable limits (<1 µg/dL) by 72 h, with concurrent decreases in triiodothyronine (T3, about a 70% decrease) and increases in TSH (TSH; about a three-fold increase). DMP 904 increased [125I]T4 total body clearance (Cl_{tb}) (38.21±10.45 mL/h) compared to control (5.61±0.59 mL/h) and phenobarbital-treated rats (7.92±1.62 mL/h). This increase in Cl_{tb} was associated with a significant increase in biliary clearance (Cl_{bile}) of unconjugated [125I]T4 (nearly 80-times control rates) and increased liver:blood ratios of T4, suggestive of enhanced hepatic uptake of T4. A single dose of DMP 904 (200 mg/kg) increased mRNA levels of hepatic

cytochrome P450s (CYP 3A1 and CYP 2B1) and UDP-glucuronosyltransferases (UGT 1A1 and UGT 1A2). DMP 904 also induced mRNAs of the canalicular transporter, multi-drug resistance protein-2 (Mrp2) and sinusoidal transporters, organic anion transporting proteins (Oatp1 and Oatp2) within 24 h. Western blot anal. confirmed DMP 904 related increases in Oatp2 protein expression. Collectively, these data suggest that DMP 904 is an agonist of the constitutive androstane receptor (CAR) and pregnane X receptor (PXR) and that the decreased serum levels of T4 and T3 resulted from increased hepatobiliary clearance. However, DMP 904 is distinguished from other compds. associated with similar effects on thyroid hormone homeostasis because its effects were primarily related to increased biliary excretion of unconjugated T4.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:222553 CAPLUS
 DOCUMENT NUMBER: 142:385821
 TITLE: Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests
 AUTHOR(S): Hogan, John B.; Hodges, Donald B., Jr; Lelas, Snjezana; Gilligan, Paul J.; McElroy, John F.; Lindner, Mark D.
 CORPORATE SOURCE: Neuroscience Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
 SOURCE: Psychopharmacology (Berlin, Germany) (2005), 178(4), 410-419
 CODEN: PSCHDL; ISSN: 0033-3158
 PUBLISHER: Springer GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP-904
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CRF1 receptor antagonists and benzodiazepines on cognitive functions)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB Benzodiazepines continue to be widely used for the treatment of anxiety, but it is well known that benzodiazepines have undesirable side effects, including sedation, ataxia, cognitive deficits, and the risk of addiction and abuse. CRF1 receptor antagonists are being developed as potential novel anxiolytics, but while CRF1 receptor antagonists seem to have a better side-effect profile than benzodiazepines with respect to sedation and ataxia, the effects of CRF1 receptor antagonists on cognitive function were not well characterized. It is somewhat surprising that the potential cognitive effects of CRF1 receptor antagonists were not more fully characterized since there is some evidence to suggest that these compounds may impair cognitive function. The Morris water maze and the delayed non-matching to position test are sensitive tests of a range of cognitive functions, including spatial learning, attention, and short-term memory, so the objective of the present experiments was to assess the effects of benzodiazepines and CRF1 receptor antagonists in these tests. The benzodiazepines chlordiazepoxide and alprazolam disrupted performance in the Morris water maze and delayed non-matching to position at doses close to their therapeutic, anxiolytic doses. In contrast, the CRF1 receptor antagonists DMP-904 and DMP-696 produced little or no impairment in the Morris water maze or delayed non-matching to position test even at doses 10-fold higher than were necessary to produce anxiolytic effects. The results of the present experiments suggest that, with respect to their effects

on cognitive functions, CRF1 receptor antagonists seem to have a wider therapeutic index than benzodiazepines.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:750991 CAPLUS
 DOCUMENT NUMBER: 141:271427
 TITLE: Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice
 AUTHOR(S): Nielsen, Darci M.; Carey, Galen J.; Gold, Lisa H.
 CORPORATE SOURCE: Pfizer, Kalamazoo, MI, 49007, USA
 SOURCE: European Journal of Pharmacology (2004), 499(1-2), 135-146
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB The development of selective corticotropin-releasing factor type-1 (CRF1) receptor antagonists represents a potential novel treatment for depression. These studies evaluated CRF1 receptor antagonists for antidepressant-like activity in mice. Subchronic dosing of both R 121919 (3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine) and DMP 696 (4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine) significantly decreased immobility time in the tail suspension test (at 30 and at 3 and 10 mg/kg, i.p., resp.). These antidepressant-like effects were observed at doses that did not impair general locomotor activity. Neither antalarmin (N-butyl-N-ethyl-[2,5,6-trimethyl-7-(2,4,6)trimethylphenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine) nor DMP 904 (4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine) had an effect indicative of antidepressant-like activity. These results suggest that the tail suspension assay may have utility to identify CRF1 receptor antagonists with antidepressant-like activity. Moreover, the results lend support to the theory that some nonpeptidic CRF1 receptor antagonists may possess antidepressant-like activity and therefore represent a promising novel pharmacotherapeutic strategy in the treatment of depression.
 REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2004:523288 CAPLUS
DOCUMENT NUMBER: 141:225452
TITLE: Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-
a]pyrimidines as potent CRF1 receptor antagonists
AUTHOR(S): Huang, Charles Q.; Wilcoxon, Keith M.; Grigoriadis,
Dimitri E.; McCarthy, James R.; Chen, Chen
CORPORATE SOURCE: Department of Medicinal Chemistry and Department of
Pharmacology, Neurocrine Biosciences, Inc., San Diego,
CA, 92129, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
14(15), 3943-3947
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:225452
IT 195054-99-0, NBI 30545 202579-74-6, DMP 904
RL: PRP (Properties)
(calculated lipophilicity of corticotropin-releasing factor receptor
antagonists)
RN 195054-99-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-
methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-74-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-
methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



GI



AB A series of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines I [R1 = Cl, O2N, Me, F3C, H2N, HO, etc.; R2 = H, Me, Cl, O2N, H2N, MeO, NO, etc.; R3, R4 = n-Pr, n-Bu, MeOCH2CH2, cyclopropylmethyl, PhCH2] was designed and synthesized as antagonists for the corticotropin-releasing factor-1 (CRF1) receptor. Several compds. such as I [R1 = Me2N; R2 = Me; R3 = R4 = n-Pr; (II)] (Ki = 10 nM) exhibited good binding affinities at the CRF1 receptor. In addition, II had adequate solubility in water.

L5 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:498562 CAPLUS

DOCUMENT NUMBER: 141:207163

TITLE: Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility

AUTHOR(S): Chen, Chen; Wilcoxon, Keith M.; Huang, Charles Q.; McCarthy, James R.; Chen, Takung; Grigoriadis, Dimitri E.

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3669-3673

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:207163


IT 195055-89-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility)

RN 195055-89-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)



IT 195054-99-0P 195055-79-9P 195055-83-5P

195055-85-7P 195055-86-8P 195055-88-0P

744222-20-6P 744222-21-7P 744222-22-8P


744222-23-9P 744222-24-0P 744222-32-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 195055-79-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-83-5 CAPLUS

CN Ethanol, 2-[[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 195055-85-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-86-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dimethoxyphenyl)-N-ethyl-2,5-dimethyl- (CA INDEX NAME)




RN 195055-88-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)



RN 744222-20-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 744222-21-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(4-methoxyphenyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 744222-22-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 744222-23-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 744222-24-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 744222-32-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[4-[2-(dimethylamino)ethoxy]phenyl]-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)



GI




I

AB In an effort to identify potent CRF1 antagonists with proper physicochem. properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (I) was found to have good binding affinity and potent antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity (log D = 2.78) and good solubility in water (>10 mg/mL), and exhibited good plasma and brain exposure when given orally.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:292574 CAPLUS
 DOCUMENT NUMBER: 140:368553
 TITLE: Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats
 AUTHOR(S): Lelas, Snjezana; Wong, Harvey; Li, Yu-Wen; Heman, Karen L.; Ward, Kathryn A.; Zeller, Kim L.; Sieracki, Kristine K.; Polino, Joseph L.; Godonis, Helen E.; Ren, Shelly X.; Yan, Xiao-Xin; Arneric, Stephen P.; Robertson, David W.; Hartig, Paul R.; Grossman, Scott; Trainor, George L.; Taub, Rebecca A.; Zaczek, Robert; Gilligan, Paul J.; McElroy, John F.
 CORPORATE SOURCE: Neuroscience Biology, Bristol-Myers Squibb Company, Wallingford, CT, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (2004), 309(1), 293-302
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
 (anxiolytic-like effects of chronic or acute corticotropin-releasing factor1 (CRF1) antagonist DMP904)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB Corticotropin-releasing factor1 (CRF1) antagonists may be effective in the treatment of anxiety disorders with fewer side effects compared with classic benzodiazepines. The behavioral effects of DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] and its effects on the hypothalamic-pituitary-adrenal (HPA) axis were related to its levels in plasma and estimated occupancy of central CRF1 receptors. DMP904 (10-30 mg/kg, p.o.) and alprazolam (10 mg/kg, p.o.) increased time spent in open arms of an elevated-plus maze. In addition, acutely or chronically (14 days) administered DMP904 (1.0-30 mg/kg, p.o.) and acute alprazolam (1.0-3.0 mg/kg, p.o.) significantly reduced exit latency in the defensive withdrawal model of anxiety in rats, suggesting that tolerance may not develop to the anxiolytic-like effects of DMP904 in this model of anxiety. Acutely, DMP904 reversed the stress-induced increase in plasma corticosterone levels in defensive

withdrawal at doses of 3.0 mg/kg and higher. These doses also resulted in levels of DMP904 in plasma similar to (for anxiolytic-like effects) or 4-fold higher (for effects on the HPA axis) than the in vitro IC50 value for binding affinity at CRF1 receptors and greater than 50% occupancy of CRF1 receptors. Unlike alprazolam, DMP904 did not produce sedation, ataxia, or chlordiazepoxide-like subjective effects (as measured by locomotor activity, rotorod performance, and chlordiazepoxide discrimination assays, resp.) at doses at least 3-fold higher than anxiolytic-like doses. In conclusion, anxiolytic-like effects and effects on the stress-activated HPA axis of DMP904 in the defensive withdrawal model of anxiety required 50% or greater occupancy of central CRF1 receptors. This level of CRF1 receptor occupancy resulted in fewer motoric side effects compared with classic benzodiazepines.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:262469 CAPLUS
 DOCUMENT NUMBER: 139:173737
 TITLE: Pharmacological characterization of a novel nonpeptide antagonist radioligand, (±)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors
 AUTHOR(S): Zhang, Ge; Huang, Ning; Li, Yu-Wen; Qi, Xiaoping; Marshall, Anne P.; Yan, Xiao-Xin; Hill, Geraldine; Rominger, Cynthia; Prakash, Shimoga R.; Bakthavatchalam, Rajagopal; Rominger, David H.; Gilligan, Paul J.; Zaczek, Robert
 CORPORATE SOURCE: CNS Diseases Research, Bristol-Myers Squibb
 SOURCE: Pharmaceutical Research Institute, Wilmington, DE, USA
 JOURNAL: Journal of Pharmacology and Experimental Therapeutics (2003), 305(1), 57-69
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: PAC (Pharmacological activity); BIOL (Biological study) (pharmacol. characterization of a novel nonpeptide antagonist radioligand, (±)-N-[2-Me-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-Me-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB The in vitro pharmacol. profile of a novel small mol. corticotropin-releasing factor 1 (CRF1) receptor antagonist, (±)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine (SN003), and the characteristics of its radioligand ([3H]SN003) are described. SN003 has high affinity and selectivity for CRF1 receptors expressed in rat cortex, pituitary, and recombinant HEK293EBNA (HEK293e) cells with resp. radiolabeled ovine CRF ([125I]oCRF) binding K_i values of 2.5, 7.9, and 6.8 nM. SN003 was shown to be a CRF1 receptor antagonist inasmuch as it inhibited CRF-induced cAMP accumulation in human CRF1HEK293e cells and CRF-stimulated ACTH hormone release from rat pituitary cells without agonist activities. Significant decreases in the B_{max} of [125I]oCRF binding by SN003 suggest that this antagonist is not simply competitive. To further explore the interaction of SN003 with the CRF1 receptors, [3H]SN003 binding to rat cortex and human CRF1HEK293e cell membranes was characterized and shown to be reversible and saturable,

with KD values of 4.8 and 4.6 nM, and Bmax values of 0.142 and 7.42 pmol/mg protein, resp. The association and dissociation rate consts. of [3H]SN003 (k+1 0.292 nM⁻¹ min⁻¹ and k-1 0.992+10⁻² min⁻¹) were also assessed using human CRF1HEK293e cell membranes, giving an equilibrium dissociation constant of 3.4 nM. Moreover, [3H]SN003 binding displayed a single affinity state and insensitivity to 5'-guanylylimidodiphosphate, consistent with characteristics of antagonist binding. Incomplete inhibition of [3H]SN003 binding by CRF peptides also suggests that SN003 is not simply competitive with CRF at CRF1 receptors. The distribution of [3H]SN003 binding sites was consistent with the expression pattern of CRF1 receptors in rat brain regions. Small mol. CRF1 antagonist radioligands like [3H]SN003 should enable a better understanding of small mol. interactions with the CRF1 receptor.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:716091 CAPLUS
 DOCUMENT NUMBER: 137:232665
 TITLE: A process for the preparation of a homochiral corticotropin releasing factor receptor ligand
 INVENTOR(S): Gilligan, Paul J.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072101	A1	20020919	WO 2002-US6834	20020306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2002240578 A1 20020924 AU 2002-240578 20020306 PRIORITY APPLN. INFO.: US 2001-275331P P 20010313 WO 2002-US6834 W 20020306				

OTHER SOURCE(S): CASREACT 137:232665

IT 457911-55-6P, (-)-7-((R)-Butan-2-ylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CRF antagonist; process for preparation of a homochiral corticotropin releasing factor receptor ligand)


RN 457911-55-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methylpropyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



AB A process for the preparation of corticotropin releasing factor receptor I was disclosed. 2-Methyl-4-methoxybenzyl bromide (prepn given) was converted to the nitrile (DMF/EtOHaq, NaCN) and acetylated (EtOAc, Na^o, reflux) and reacted with hydrazine to give an intermediate pyrazole. This was reacted with Et acetoacetate (HOAc, reflux) to form 7-hydroxy-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (II). II was treated with POCl₃ (PhMe, DIEA) and the chloride displaced with (R)-2-butylamine to afford I. I is used in treating anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:184863 CAPLUS

DOCUMENT NUMBER: 136:221516

TITLE: Hair growth stimulants containing CRF1 receptor antagonists

INVENTOR(S): Ikeda, Akiko; Okuyama, Shigeru; Shibasaki, Tamotsu; Kawana, Seiji; Kaneko, Katsumi

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019975	A1	20020314	WO 2001-JP7537	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001084417	A5	20020322	AU 2001-84417	20010831
PRIORITY APPLN. INFO.:			JP 2000-269291	A 20000905
			WO 2001-JP7537	W 20010831


OTHER SOURCE(S): MARPAT 136:221516

IT 195054-99-0 202579-74-6

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair growth stimulants containing CRF1 receptor antagonists)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB Disclosed are hair growth stimulants containing a corticotropin release factor (CRF) 1 receptor antagonist as the active ingredient. A CRF1 receptor antagonist 2-[N-(2-methylthio-4-isopropylphenyl)-N-ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine-1-yl]-6-methylpyrimidine showed keratinocyte cell proliferation promoting effect in cultured human epidermal keratinocyte cells.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:813420 CAPLUS
 DOCUMENT NUMBER: 135:344507
 TITLE: Preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: U.S., 57 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313124	B1	20011106	US 1998-14734	19980128
CA 2532925	A1	19980129	CA 1997-2532925	19970723
US 6124289	A	20000926	US 1997-899242	19970723
EP 1908764	A1	20080409	EP 2007-15514	19970723
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, AL, LT, LV, RO, SI				
ZA 9706603	A	19990125	ZA 1997-6603	19970724
US 6136809	A	20001024	US 1998-14999	19980128
LT 4680	B	20000725	LT 1999-8	19990125
CA 2314613	A1	19990805	CA 1999-2314613	19990128
CA 2614603	A1	19990805	CA 1999-2614603	19990128
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
EP 1344779	A1	20030917	EP 2003-75887	19990128
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	T	20040515	AT 1999-904382	19990128
PT 1049699	T	20040831	PT 1999-904382	19990128
CN 1542010	A	20041103	CN 2003-10122546	19990128
ES 2218991	T3	20041116	ES 1999-904382	19990128
SG 111076	A1	20050530	SG 2002-4556	19990128
AT 301657	T	20050815	AT 2003-75887	19990128
PT 1344779	T	20051031	PT 2003-75887	19990128
ES 2247478	T3	20060301	ES 2003-75887	19990128
TW 520372	B	20030211	TW 1999-88102636	19990223
MX 2000PA06495	A	20011011	MX 2000-PA6495	20000629
US 20030008885	A1	20030109	US 2001-930782	20010816
US 7094782	B1	20060822	US 2003-703235	20031107
HK 1060348	A1	20051021	HK 2004-101985	20040317

JP 2005097257	A	20050414	JP 2004-216483	20040723
US 20060252756	A1	20061109	US 2006-477680	20060629
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724

US 1997-899242	A2	19970723
US 1996-686047	A	19960724
CA 1997-2259583	A3	19970723
EP 1997-936222	A3	19970723
JP 1998-507233	A3	19970723
US 1998-14734	A	19980128
US 1998-15001	A	19980128
US 1998-15002	A	19980128
CA 1999-2314613	A3	19990128
EP 1999-904382	A3	19990128
WO 1999-US1824	W	19990128
US 2001-930782	B1	20010816
US 2003-703235	A1	20031107


OTHER SOURCE(S): MARPAT 135:344507

IT 202579-74-6P 202579-75-7P 202579-76-8P
 202579-77-9P 202579-85-9P 202579-86-0P
 202579-89-3P 202579-91-7P 202579-93-9P
 202579-94-0P 202579-95-1P 202579-96-2P
 202580-25-4P 202580-26-5P 202580-27-6P
 202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-85-9 CAPLUS
 CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alkyl, alkenyl, etc.; R₁ = H, alkyl, alkenyl, etc.; R₂ = H, alkyl, alkenyl, etc.; R₃ = H, SH, OH, etc.; R₁₄ = C₁-10 alkyl, C₃-10 alkenyl, C₃-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POCl₃ and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-C₁₂H₃].

REFERENCE COUNT: 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 2001:796238 CAPLUS
 DOCUMENT NUMBER: 135:339292
 TITLE: Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
 INVENTOR(S): Fossa, Anthony A.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 58 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1149583	A2	20011031	EP 2001-303033	20010330
EP 1149583	A3	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2001001456	A	20011204	BR 2001-1456	20010411
MX 2001PA03855	A	20020604	MX 2001-PA3855	20010411
CA 2344089	A1	20011013	CA 2001-2344089	20010412
US 20010041673	A1	20011115	US 2001-834477	20010413
PRIORITY APPLN. INFO.:			US 2000-196698P	P 20000413

OTHER SOURCE(S): MARPAT 135:339292


IT 195054-99-0 202579-86-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations of corticotropin releasing factor antagonists and growth hormone secretagogues)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB This invention is directed to pharmaceutical compns. comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compds. or said prodrugs (Markush structures given). The invention is also directed to the use of such compns. in the treatment or prevention of osteoporosis and heart-related diseases (including congestive heart failure) in mammals, particularly humans (no data).


L5 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:338070 CAPLUS
DOCUMENT NUMBER: 134:336224
TITLE: Use of corticotropin releasing factor (CRF)
antagonists for treating syndrome X
INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026
EP 1097709	A3	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AU 776724	B2	20040916	AU 2000-66695	20001024
ZA 2000006008	A	20020426	ZA 2000-6008	20001026
US 6589947	B1	20030708	US 2000-696822	20001026
CA 2325069	A1	20010429	CA 2000-2325069	20001027
HU 2000004194	A2	20011228	HU 2000-4194	20001027
HU 2000004194	A3	20020328		
NZ 507825	A	20041126	NZ 2000-507825	20001027
US 20070117805	A1	20070524	US 2006-580996	20061013
PRIORITY APPLN. INFO.:			US 1999-162340P	P 19991029
			US 2000-559384	A3 20000427
			US 2002-80174	A1 20020219
			US 2003-721318	A1 20031125

OTHER SOURCE(S): MARPAT 134:336224

IT 195054-99-0 202579-86-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)
RN 195054-99-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

L5 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2001:247337 CAPLUS
DOCUMENT NUMBER: 134:280853
TITLE: Preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists
INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum, Charles; Tran, Jennifer; Giangordano, Mark; Griffith, David Andrew; Carpino, Philip Albert
PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023388	A2	20010405	WO 2000-US26885	20000929
WO 2001023388	A3	20011018		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2379633	A1	20010405	CA 2000-2379633	20000929
CA 2379633	C	20060620		
EP 1218381	A2	20020703	EP 2000-967132	20000929
EP 1218381	B1	20061206		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6476038	B1	20021105	US 2000-676972	20000929
HU 2002003131	A2	20030128	HU 2002-3131	20000929
HU 2002003131	A3	20040628		
JP 2003510326	T	20030318	JP 2001-526540	20000929
AT 347553	T	20061215	AT 2000-967132	20000929
ES 2277855	T3	20070801	ES 2000-967132	20000929
BG 106507	A	20021229	BG 2002-106507	20020311
NO 2002001357	A	20020523	NO 2002-1357	20020319
ZA 2002002517	A	20030328	ZA 2002-2517	20020328
JP 2007077144	A	20070329	JP 2006-241067	20060906
PRIORITY APPLN. INFO.:			US 1999-156868P	P 19990930
			JP 2001-526540	A3 20000929
			WO 2000-US26885	W 20000929
OTHER SOURCE(S):	MARPAT 134:280853			
IT 332225-31-7P 332225-68-0P				
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists)			
RN 332225-31-7 CAPLUS				
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)				




RN 332225-68-0 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; N, CR14; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted (CH₂)_m (wherein m = 1-3); B = (un)substituted (CH₂)_n (n = 0-3); R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5, R6 = H, alkyl, cycloalkyl, etc.] that are selective modulators of NPY1 receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II was described. The NPY1 receptor binding affinity for the compds. I, expressed as a K_i, ranges from 0.1 nM to 10 μM. The compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Compds. I were also tested for CRF1 receptor binding affinity.

L5 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:247336 CAPLUS

DOCUMENT NUMBER: 134:280866

TITLE: Preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors

INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum, Charles; Tran, Jennifer; Giangiorano, Mark; Griffith, David Andrew; Carpino, Philip Albert

PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.; De Lombaert, Stephane

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001023387	A2	20010405	WO 2000-US26887	20000929
WO 2001023387	A3	20020124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2379585	A1	20010405	CA 2000-2379585	20000929
CA 2379585	C	20060620		
US 6372743	B1	20020416	US 2000-676970	20000929
EP 1218379	A2	20020703	EP 2000-967134	20000929
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
HU 2002002678	A2	20021228	HU 2002-2678	20000929
HU 2002002678	A3	20040628		
JP 2003510325	T	20030318	JP 2001-526539	20000929
US 20030069246	A1	20030410	US 2002-83245	20020225
BG 106506	A	20021229	BG 2002-106506	20020311
NO 2002001356	A	20020523	NO 2002-1356	20020319
ZA 2002002519	A	20031128	ZA 2002-2519	20020328
PRIORITY APPLN. INFO.:			US 1999-156869P	P 19990930
			US 2000-676970	A1 20000929
			WO 2000-US26887	W 20000929

OTHER SOURCE(S): MARPAT 134:280866

IT 332178-43-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)

RN 332178-43-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-,
hydrochloride (9CI) (CA INDEX NAME)



IT 332178-33-3P 332178-41-3P 332178-42-4P
 332178-44-6P 332178-45-7P 332178-46-8P
 332178-47-9P 332178-48-0P 332178-49-1P
 332178-50-4P 332178-51-5P 332178-52-6P
 332178-53-7P 332178-54-8P 332178-55-9P
 332178-56-0P 332178-57-1P 332178-59-3P
 332178-60-6P 332178-61-7P 332178-62-8P
 332178-63-9P 332178-64-0P 332178-66-2P
 332178-68-4P 332178-69-5P 332178-76-4P
 332178-79-7P 332178-85-5P 332178-86-6P
 332178-87-7P 332178-88-8P 332178-89-9P
 332178-90-2P 332178-91-3P 332178-92-4P
 332178-94-6P 332178-95-7P 332178-97-9P
 332178-99-1P 332179-00-7P 332179-01-8P
 332179-05-2P 332179-24-5P 332179-25-6P
 332179-26-7P 332179-27-8P 332179-28-9P
 332179-29-0P 332179-30-3P 332179-31-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)


RN 332178-33-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-41-3 CAPLUS
CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 332178-42-4 CAPLUS
 CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332178-44-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-

(9CI) (CA INDEX NAME)



RN 332178-45-7 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 332178-46-8 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-
(9CI) (CA INDEX NAME)




RN 332178-47-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-N-[(6-methyl-2-piperidinyl)methyl]- (CA INDEX NAME)




RN 332178-48-0 CAPLUS

CN 1-Butanol, 2-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (CA INDEX NAME)



RN 332178-49-1 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-50-4 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-ethyl- (9CI) (CA

INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	332178-51-5	CAPLUS
CN	1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[4-(4-morpholinyl)cyclohexyl]- (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A



RN 332178-52-6 CAPLUS
CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332178-53-7 CAPLUS
 CN 1,2-Propanediol, 3-[[[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (CA INDEX NAME)



RN 332178-54-8 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-(2-methylpropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-55-9 CAPLUS
CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-
dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-methylethyl]amino]- (CA
INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-56-0 CAPLUS
 CN Cyclohexanol, 2-[[2-[[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (CA INDEX NAME)




RN 332178-57-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4,4,4-trifluorobutyl)- (9CI)
 (CA INDEX NAME)



RN 332178-59-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,2-trifluoroethyl)- (9CI)
 (CA INDEX NAME)




RN 332178-60-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(trifluoromethyl)cyclohexyl]-(9CI) (CA INDEX NAME)



RN 332178-61-7 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[4-(trifluoromethyl)cyclohexyl]-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 332178-62-8 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2-difluoroethyl)- (9CI) (CA INDEX NAME)




RN 332178-63-9 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 332178-64-0 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluorocyclohexyl)- (9CI) (CA INDEX NAME)




RN 332178-66-2 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 332178-68-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)-(9CI) (CA INDEX NAME)




RN 332178-69-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)



RN 332178-76-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)- (9CI) (CA INDEX NAME)




RN 332178-79-7 CAPLUS
 CN 1,2-Ethanediamine, N-3-cyclohexen-1-yl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332178-85-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(phenylmethyl)-4-piperidinyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-86-6 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-87-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-88-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-4-piperidinyll)-(9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-89-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-90-2 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332178-91-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-3-piperidiny)- (9CI)
(CA INDEX NAME)



RN 332178-92-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-4-piperidinyloctyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-94-6 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(3-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-95-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(4-pyridinylmethyl)-4-

piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-97-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-99-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-00-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-01-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyll]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-05-2 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332179-24-5 CAPLUS
CN 4-Piperidinamine, 1-acetyl-N-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 332179-25-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-26-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-ethoxy-4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 332179-27-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 332179-28-9 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 332179-29-0 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-30-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-31-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A



IT 332179-74-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
RN 332179-74-5 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; X = N, CR₁₄; R₁ = H, alkyl, cycloalkyl, etc.; R₂ = H, alkyl which optionally forms (un)substituted aminocarbocycle or aminoheterocycle with A and B, etc.; R₂ and R₆ with 2 N atoms to which they are bound, form (un)substituted aminoheterocycle; R₂ and A form (un)substituted aminocarbocycle, aminoheterocycle; A, B = (un)substituted alkyl; A and B form (un)substituted carbocycle; B and R₆ form (un)substituted aminocarbocycle; R₃ = H, alkyl, cycloalkyl, etc.; R₄ = (un)substituted aryl, heteroaryl; R₅ = (un)substituted (cycloalkyl)alkyl, alkenyl, alkynyl, etc.; R₆ = H, alkyl, cycloalkyl, etc.; R₁₄ = H, alkyl, etc.] which are selective modulators of NPY₁ receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were prepared. E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II, was described. The NPY₁ binding affinity for the compds. I, expressed as a K_i value, ranges from 0.1 nM to 10 μM. Compds. I are also useful as probes for the localization of NPY₁ receptors and as stds. in assays for NPY₁ receptor binding. Methods of using the compds. I in receptor localization studies are given.

L5 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:185043 CAPLUS

DOCUMENT NUMBER: 134:217215

TITLE: Use of CRF antagonists and related compositions for modifying circadian rhythm and treatment of depression and other conditions

INVENTOR(S): Chen, Yuhpyng Liang

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1082960	A2	20010314	EP 2000-307074	20000818
EP 1082960	A3	20020320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6432989	B1	20020813	US 2000-587007	20000605
EP 1449532	A1	20040825	EP 2004-12293	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2001097889	A	20010410	JP 2000-251836	20000823
HU 2000003386	A2	20010730	HU 2000-3386	20000824
HU 2000003386	A3	20030828		
ZA 2000004362	A	20020225	ZA 2000-4362	20000824
CA 2316662	A1	20010227	CA 2000-2316662	20000825
NZ 506562	A	20020927	NZ 2000-506562	20000825
AU 776077	B2	20040826	AU 2000-53644	20000825
US 20020156089	A1	20021024	US 2002-161816	20020604
US 20040082597	A1	20040429	US 2003-676201	20031001
PRIORITY APPLN. INFO.:			US 1999-151183P	P 19990827
			US 2000-587007	A3 20000605
			EP 2000-307074	A3 20000818
			US 2002-161816	A3 20020604


IT 195054-99-0 202579-86-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonists and related compns. for modifying circadian rhythm and treatment of depression and other conditions, and use with other agents)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB A corticotropin releasing factor (CRF) antagonist is administered to treat disorders that can be treated by altering circadian rhythm, as well as depression (in which a second compound for treating depression is administered, the second compound having an onset of action that is delayed with respect to that of the CRF antagonist). Methods for treating cardiovascular diseases, migraine, non-migraine headaches, and emesis are also disclosed.

L5 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:131201 CAPLUS
DOCUMENT NUMBER: 134:178572
TITLE: Preparation of azolo triazines and pyrimidines as
corticotropin releasing factor (CRF) antagonists
INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
Argyrios Georgios
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Co., USA
SOURCE: U.S., 90 pp., Cont.-in-part of U. S. Ser. No. 899,242.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191131	B1	20010220	US 1998-15002	19980128
CA 2532925	A1	19980129	CA 1997-2532925	19970723
US 6124289	A	20000926	US 1997-899242	19970723
EP 1908764	A1	20080409	EP 2007-15514	19970723
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, AL, LT, LV, RO, SI				
ZA 9706603	A	19990125	ZA 1997-6603	19970724
US 6136809	A	20001024	US 1998-14999	19980128
LT 4680	B	20000725	LT 1999-8	19990125
CA 2314613	A1	19990805	CA 1999-2314613	19990128
CA 2614603	A1	19990805	CA 1999-2614603	19990128
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
EP 1344779	A1	20030917	EP 2003-75887	19990128
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	T	20040515	AT 1999-904382	19990128
PT 1049699	T	20040831	PT 1999-904382	19990128
CN 1542010	A	20041103	CN 2003-10122546	19990128
ES 2218991	T3	20041116	ES 1999-904382	19990128
SG 111076	A1	20050530	SG 2002-4556	19990128
AT 301657	T	20050815	AT 2003-75887	19990128
PT 1344779	T	20051031	PT 2003-75887	19990128
ES 2247478	T3	20060301	ES 2003-75887	19990128
TW 520372	B	20030211	TW 1999-88102636	19990223
US 6358950	B1	20020319	US 2000-696759	20001026
HK 1060348	A1	20051021	HK 2004-101985	20040317
JP 2005097257	A	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724

US 1997-899242	A2 19970723
US 1996-686047	A 19960724
CA 1997-2259583	A3 19970723
EP 1997-936222	A3 19970723
JP 1998-507233	A3 19970723
US 1998-14734	A 19980128
US 1998-15001	A 19980128
US 1998-15002	A 19980128
CA 1999-2314613	A3 19990128
EP 1999-904382	A3 19990128
WO 1999-US1824	W 19990128


OTHER SOURCE(S): MARPAT 134:178572

IT 202579-74-6P 202579-75-7P 202579-76-8P
 202579-77-9P 202579-85-9P 202579-86-0P
 202579-89-3P 202579-91-7P 202579-93-9P
 202579-94-0P 202579-95-1P 202579-96-2P
 202580-25-4P 202580-26-5P 202580-27-6P
 202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolo-fused triazines and pyrimidines as CRF antagonists)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-85-9 CAPLUS
 CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alk(en/yn)yl, halo, etc.; R1, R2 = H, alk(en/yn)yl, halo, etc.; R3 = H, SH, aryl, etc.; R14 = (un)substituted alk(en/yn)yl, cycloalkyl(alkyl)], useful in treating CRF-related disorders, particularly anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-2,5-dimethyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl3 and PhNEt2 to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound I [A = CH; R1 = Me; R3 = NHCHEt2; Z = CMe; Ar = 2-Cl-4-MeC6H3]. The compds. I are effective at 0.002-200 mg/kg/day.

REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:307132 CAPLUS
 DOCUMENT NUMBER: 132:321873
 TITLE: Azolo triazines and pyrimidines useful as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios
 Georgios
 PATENT ASSIGNEE(S): DuPont Pharmaceuticals Co., USA
 SOURCE: U.S., 86 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060478	A	20000509	US 1998-15001	19980128
CA 2532925	A1	19980129	CA 1997-2532925	19970723
US 6124289	A	20000926	US 1997-899242	19970723
EP 1908764	A1	20080409	EP 2007-15514	19970723
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, AL, LT, LV, RO, SI				
ZA 9706603	A	19990125	ZA 1997-6603	19970724
US 6136809	A	20001024	US 1998-14999	19980128
LT 4680	B	20000725	LT 1999-8	19990125
CA 2314613	A1	19990805	CA 1999-2314613	19990128
CA 2614603	A1	19990805	CA 1999-2614603	19990128
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
EP 1344779	A1	20030917	EP 2003-75887	19990128
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	T	20040515	AT 1999-904382	19990128
PT 1049699	T	20040831	PT 1999-904382	19990128
CN 1542010	A	20041103	CN 2003-10122546	19990128
ES 2218991	T3	20041116	ES 1999-904382	19990128
SG 111076	A1	20050530	SG 2002-4556	19990128
AT 301657	T	20050815	AT 2003-75887	19990128
PT 1344779	T	20051031	PT 2003-75887	19990128
ES 2247478	T3	20060301	ES 2003-75887	19990128
TW 520372	B	20030211	TW 1999-88102636	19990223
HK 1060348	A1	20051021	HK 2004-101985	20040317
JP 2005097257	A	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724
			US 1997-899242	A2 19970723

US 1996-686047	A 19960724
CA 1997-2259583	A3 19970723
EP 1997-936222	A3 19970723
JP 1998-507233	A3 19970723
US 1998-14734	A 19980128
US 1998-15001	A 19980128
US 1998-15002	A 19980128
CA 1999-2314613	A3 19990128
EP 1999-904382	A3 19990128
WO 1999-US1824	W 19990128

OTHER SOURCE(S): MARPAT 132:321873

IT 202579-74-6P 202579-75-7P 202579-76-8P
 202579-77-9P 202579-85-9P 202579-86-0P
 202579-89-3P 202579-91-7P 202579-93-9P
 202579-94-0P 202579-95-1P 202579-96-2P
 202580-25-4P 202580-26-5P 202580-27-6P
 202580-28-7P 202580-58-3P 234777-26-5P
 234777-27-6P 234777-36-7P 234777-37-8P
 234777-42-5P 234777-44-7P 234777-46-9P
 234777-47-0P 234777-48-1P 234777-49-2P
 234777-51-6P 234777-52-7P 234778-37-1P
 234778-38-2P 234778-39-3P 234778-40-6P
 234778-41-7P 234778-42-8P 234778-43-9P
 234778-44-0P 234778-45-1P 234778-46-2P
 234778-47-3P 234778-48-4P 234778-49-5P
 234778-50-8P 234778-51-9P 234778-52-0P
 267233-60-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of azolo-fused triazines and pyrimidines as

CRF

antagonists)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-76-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-77-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-85-9 CAPLUS


CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-26-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-27-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-36-7 CAPLUS

CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 234777-37-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-42-5 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 234777-44-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



RN 234777-46-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-47-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-48-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-49-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-51-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-52-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-37-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)




RN 234778-38-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-39-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-40-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)



RN 234778-41-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-42-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-43-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-44-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-45-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)




RN 234778-46-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2,5-dimethylphenyl)-
N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-52-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)






RN 267233-60-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



GI



AB Corticotropin releasing factor (CRF) antagonists (no data) of formulas I and II are disclosed [wherein A = N or CR; Z = N or CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, pyrimidinyl, indanyl, tetralinyl, addnl. selected heterocycles; R = H, alk(en/yn)yl, cycloalkyl(alkyl), halo, cyano, haloalkyl; R₁, R₂ = H, groups listed for R, NH₂ or derivs., OH or derivs., SH or derivs., addnl. substituted alkyls; R₃ = H, OH or derivs., SH or derivs., acyl, CO₂H or esters, NH₂ or derivs., aryl, heteroaryl, alk(en/yn)yl, etc.; R₄ = (un)substituted alk(en/yn)yl or cycloalkyl(alkyl)]. The compds. are of use in the treatment of CRF-related disorders, particularly anxiety and depression, as well as other psychiatric, neurol., immunol., cardiovascular, and psychopathol. disorders. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl₃ and PhNEt₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound III.

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:125866 CAPLUS

DOCUMENT NUMBER: 132:231516

TITLE: The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist

AUTHOR(S): Gilligan, Paul J.; Baldauf, Caryn; Cocuzza, Anthony; Chidester, Dennis; Zaczek, Robert; Fitzgerald, Lawrence W.; McElroy, John; Smith, Mark A.; Shen, H.-S. L.; Saye, Jo Anne; Christ, David; Trainor, George; Robertson, David W.; Hartig, Paul

CORPORATE SOURCE: Chemical and Physical Sciences Department, Experimental Station, DuPont Pharmaceuticals Co., Wilmington, DE, 10880-0500, USA

SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(1), 181-189
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 202579-74-6P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)

RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



IT 202579-75-7 202579-85-9 202579-86-0

202579-89-3 202579-91-7 202579-93-9

202579-94-0 202579-95-1 202579-96-2

202580-25-4 202580-27-6 202580-28-7


262297-99-4 262298-00-0 262298-01-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)


RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-85-9 CAPLUS

CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)



RN 262297-99-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 262298-00-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)



RN 262298-01-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



AB Structure-activity relationship studies led to the discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (compound 11-31, DMP904), whose pharmacol. profile strongly supports the hypothesis that hCRF1 antagonists may be potent anxiolytic drugs. Compound 11-31 (hCRF1 $K_i = 1.0 \pm 0.2$ nM ($n = 8$)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells ($IC_{50} = 10.0 \pm 0.01$ nM vs. 10 nM r/hCRF, $n = 8$); α -helical CRF(9-41) had weaker potency ($IC_{50} = 286 \pm 63$ nM, $n = 3$). Analog 11-31 had good oral activity in the rat situational anxiety test; the min. ED for 11-31 was 0.3 mg/kg, orally. Maximal efficacy (approx. 57% reduction in latency time in the dark compartment) was observed at this dose. Chlordiazepoxide caused a 72% reduction in latency at 20 mg/kg, orally. CP154526-1 (30 mg/kg, orally) was inactive in this test. Compound 11-31 did not inhibit open-field locomotor activity at 10, 30, and 100 mg/kg, orally in rats. In beagle dogs, this compound (5 mg/kg, i.v., orally) afforded good plasma levels. The key i.v. pharmacokinetic parameters were $t_{1/2}$, CL and $V_{d,ss}$ values equal to 46.4 ± 7.6 h, 0.49 ± 0.08 L/kg/h and 23.0 ± 4.2 L/kg, resp. After oral dosing, the mean C_{max} , T_{max} , $t_{1/2}$ and bioavailability values were equal to 1260 ± 290 nM, 0.75 ± 0.25 h, 45.1 ± 10.2 h and 33.1%, resp. The overall rat behavioral profile of this compound suggests that it may be an anxiolytic drug with a low motor side effect liability.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1999:495296 CAPLUS
DOCUMENT NUMBER: 131:144616
TITLE: Preparation of azolotriazines and -pyrimidines as
corticotropin releasing factor (CRF) antagonists
INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
Argyrios Georgios
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6060478	A	20000509	US 1998-15001	19980128
US 6191131	B1	20010220	US 1998-15002	19980128
US 6313124	B1	20011106	US 1998-14734	19980128
CA 2314613	A1	19990805	CA 1999-2314613	19990128
AU 9924787	A	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
AT 264860	T	20040515	AT 1999-904382	19990128
ZA 9900843	A	20000802	ZA 1999-843	19990203
MX 2000PA06495	A	20011011	MX 2000-PA6495	20000629
AU 2002300983	A1	20030220	AU 2002-300983	20020911
PRIORITY APPLN. INFO.:			US 1998-14734	A 19980128
			US 1998-15001	A 19980128
			US 1998-15002	A 19980128
			US 1996-23290P	P 19960724
			US 1997-899242	A2 19970723
			AU 1999-24787	A3 19990128
			WO 1999-US1824	W 19990128
IT 202579-86-0P 234777-26-5P 234777-27-6P				
234777-36-7P 234777-37-8P 234777-42-5P				
234777-44-7P 234777-46-9P 234777-47-0P				
234777-48-1P 234777-49-2P 234777-51-6P				
234777-52-7P 234778-37-1P 234778-38-2P				
234778-39-3P 234778-40-6P 234778-41-7P				
234778-42-8P 234778-43-9P 234778-44-0P				
234778-45-1P 234778-46-2P 234778-47-3P				
234778-48-4P 234778-49-5P 234778-50-8P				
234778-51-9P 234778-52-0P 234778-53-1P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

(preparation of azolotriazines and -pyrimidines as CRF antagonists for treatment of anxiety, depression, and other psychiatric, neurol. disorders)


RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-27-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-36-7 CAPLUS

CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 234777-37-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-42-5 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 234777-44-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-46-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-47-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-48-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-49-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-51-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5,6-trimethyl- (CA INDEX NAME)



RN 234777-52-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-37-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)




RN 234778-38-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-39-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-40-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-41-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-42-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-43-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-44-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



RN 234778-45-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)




RN 234778-46-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-52-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)





RN 234778-53-1 CAPLUS

CN Butanenitrile, 4-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R1 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R2 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R3 = H, SH, OH, etc.; R14 = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POCl3 and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R1 = Me; R3 = Me; R14 = NHCH(CH2OMe)2; Ar = 2,4-Cl2C6H3].

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:87733 CAPLUS
 DOCUMENT NUMBER: 128:154103
 TITLE: Preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): Arvanitis, Argyrios Georgious; Chorvat, Robert John
 PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
 SOURCE: PCT Int. Appl., 225 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803510	A1	19980129	WO 1997-US13072	19970723
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2259583	A1	19980129	CA 1997-2259583	19970723
CA 2532925	A1	19980129	CA 1997-2532925	19970723
AU 9738942	A	19980210	AU 1997-38942	19970723
AU 747708	B2	20020523		
EP 915880	A1	19990519	EP 1997-936222	19970723
EP 915880	B1	20071010		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1225637	A	19990811	CN 1997-196525	19970723
CN 1104432	B	20030402		
BR 9710544	A	19990817	BR 1997-10544	19970723
US 6124289	A	20000926	US 1997-899242	19970723
HU 2001002187	A2	20011128	HU 2001-2187	19970723
HU 2001002187	A3	20021228		
JP 2002513382	T	20020508	JP 1998-507233	19970723
EE 4316	B1	20040615	EE 1999-19	19970723
RO 121272	B1	20070228	RO 1999-78	19970723
AT 375344	T	20071015	AT 1997-936222	19970723
PL 195762	B1	20071031	PL 1997-331523	19970723
ES 2294800	T3	20080401	ES 1997-936222	19970723
EP 1908764	A1	20080409	EP 2007-15514	19970723
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, AL, LT, LV, RO, SI				
ZA 9706603	A	19990125	ZA 1997-6603	19970724
TW 542827	B	20030721	TW 1997-86110640	19970725
TW 238164	B	20050821	TW 2003-92105694	19970725
MX 9900633	A	20020131	MX 1999-633	19990115
LV 12292	B	19991120	LV 1999-13	19990120
NO 9900264	A	19990310	NO 1999-264	19990121
NO 315610	B1	20030929		
LT 4680	B	20000725	LT 1999-8	19990125
CN 1327793	A	20011226	CN 2001-120849	20010530
AU 773039	B2	20040513	AU 2002-23236	20020312
CN 1388126	A	20030101	CN 2002-118589	20020425
JP 2005097257	A	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724
			US 1996-686047	A 19960724
			US 1997-899242	A 19970723
			AU 1997-38942	A3 19970723
			CA 1997-2259583	A3 19970723

EP 1997-936222 A3 19970723
 JP 1998-507233 A3 19970723
 WO 1997-US13072 W 19970723


OTHER SOURCE(S): MARPAT 128:154103

IT 202579-74-6P 202579-75-7P 202579-76-8P
 202579-77-9P 202579-85-9P 202579-86-0P
 202579-89-3P 202579-91-7P 202579-93-9P
 202579-94-0P 202579-95-1P 202579-96-2P
 202580-25-4P 202580-26-5P 202580-27-6P
 202580-28-7P 202580-43-6P 202580-46-9P
 202580-48-1P 202580-50-5P 202580-58-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 202579-85-9 CAPLUS
 CN Propanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202580-43-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-46-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,3-dimethylphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-48-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-50-5 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₁ = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₂ = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₃ = H, SH, OH, etc.; R₁₄ = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POC13 and N,N-dimethylaniline followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxypropyl-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-C₁₂H₃].

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:542450 CAPLUS
DOCUMENT NUMBER: 127:220669
TITLE: Pyrazolopyrimidines as CRF receptor antagonists
INVENTOR(S): Chen, Chen; Webb, Thomas R.; McCarthy, James R.;
Moran, Terence J.; Wilcoxon, Keith M.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.; Neurocrine
Biosciences, Inc.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729109	A1	19970814	WO 1997-EP459	19970130
W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2233285	A1	19970814	CA 1997-2233285	19970130
CA 2233285	C	20060704		
AU 9715991	A	19970828	AU 1997-15991	19970130
AU 713673	B2	19991209		
EP 880523	A1	19981202	EP 1997-902295	19970130
EP 880523	B1	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1205009	A	19990113	CN 1997-191382	19970130
CN 1090189	B	20020904		
HU 9900575	A2	19990628	HU 1999-575	19970130
HU 9900575	A3	20011128		
BR 9707391	A	19990720	BR 1997-7391	19970130
NZ 330119	A	20000228	NZ 1997-330119	19970130
JP 2000503661	T	20000328	JP 1997-528123	19970130
JP 3356291	B2	20021216		
JP 2002121194	A	20020423	JP 2001-265611	19970130
EE 4282	B1	20040415	EE 1998-124	19970130
PL 191271	B1	20060428	PL 1997-327284	19970130
AT 336495	T	20060915	AT 1997-902295	19970130
ES 2168237	T3	20070401	ES 1997-902295	19970130
IN 1998CA00198	A	20050311	IN 1998-CA198	19970203
TW 449599	B	20010811	TW 1997-86101373	19970205
ZA 9700989	A	19980806	ZA 1997-989	19970206
NO 9801357	A	19980803	NO 1998-1357	19980325
NO 310292	B1	20010618		
US 20030125341	A1	20030703	US 1999-117717	19990302
US 6664261	B2	20031216		
US 20040127483	A1	20040701	US 2003-665740	20030919
US 7074797	B2	20060711		
US 20060270659	A1	20061130	US 2006-413610	20060428
PRIORITY APPLN. INFO.:			US 1996-11279P	P 19960207
			US 1996-27688P	P 19961008
			JP 1997-528123	A3 19970130
			WO 1997-EP459	W 19970130

US 1999-117717 A1 19990302
US 2003-665740 A1 20030919


OTHER SOURCE(S): MARPAT 127:220669

IT 195054-99-0P 195055-34-6P 195055-35-7P
195055-36-8P 195055-37-9P 195055-38-0P
195055-39-1P 195055-79-9P 195055-80-2P
195055-81-3P 195055-82-4P 195055-83-5P
195055-85-7P 195055-86-8P 195055-87-9P
195055-88-0P 195055-89-1P 195055-90-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 195055-34-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dimethoxyphenyl)-5-methyl-N-propyl- (CA INDEX NAME)




RN 195055-35-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-methyl-N,N-dipropyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-36-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-5-methyl-N-propyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-37-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-5-methyl-N-propyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-38-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-N-ethyl-5-methyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-39-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)



RN 195055-79-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-80-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 195055-81-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-(2,4-dimethoxyphenyl)-5-methyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-82-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 195055-83-5 CAPLUS

CN Ethanol, 2-[[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 195055-85-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-86-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dimethoxyphenyl)-N-ethyl-2,5-dimethyl- (CA INDEX NAME)




RN 195055-87-9 CAPLUS
 CN 2-Propanol, 1-[[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)




RN 195055-88-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-89-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)



RN 195055-90-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(3-methoxyphenyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



GI



AB Title compds. I [R = (un)substituted Ph, pyridyl; R1 = substituted NH2, (un)substituted alkoxy; R2 = alkyl, alkoxy, alkylthio; R3 = H, alkyl, alkylsulfonyl, alkylsulfoxy, alkylthio] having CRF receptor antagonistic properties, were prepared Thus, I [R = 2,4-Cl2C6H3, R1 = N-propyl-N-cyclopropylmethylamino, R2 = Me, R3 = H, II] was obtained by treating 3-amino-4-(2,4-dichlorophenyl)pyrazole with MeCOCH2CO2Et, chlorinating I [R = 2,4-Cl2C6H3, R1 = OH, R2 = Me, R3 = H] and aminating I [R1 = Cl]. II had a Ki for CRF receptor inhibition of <250 nM.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	170.70	349.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-24.00	-24.00

STN INTERNATIONAL LOGOFF AT 16:42:34 ON 13 APR 2008